GSK2983559 active metabolite is an active metabolite of GSK2983559, also is a receptor interacting protein-2 (RIP2) kinase inhibitor extracted from patent WO/2014043446 A1, compound example 1.
[1] Casillas, LN, et al. WO2014043446A1.
| 规格 | 价格 | 库存 | 数量 | 操作 |
|---|---|---|---|---|
| 1mg | ¥432.00 | 现货 | 1 | |
| 5mg | ¥1,080.00 | 现货 | 1 | |
| 10mg | ¥1,710.00 | 现货 | 1 | |
| 50mg | ¥5,850.00 | 现货 | 1 | |
| 100mg | ¥9,450.00 | 现货 | 1 | |
| 10mM (in 1mL DMSO) | ¥1,089.00 | 现货 | 1 |
















GSK2983559 active metabolite is an active metabolite of GSK2983559, also is a receptor interacting protein-2 (RIP2) kinase inhibitor extracted from patent WO/2014043446 A1, compound example 1.
[1] Casillas, LN, et al. WO2014043446A1.
Animal experiment: | Rats[1] Rats are orally pre-dosed with RIP2 kinase inhibitor 1, at a dose of 2 mg/kg (8 rats) and with Prednisolone (8 rats, used as a positive control), followed by dosing with L18-MDP (50 μg/rat) 0.25 h/min after pre-dosing. Combined cytokine levels (IL8, TNFa, IL6 and IL-Ιβ) in whole blood samples taken from the rats in this study are measured using an antibody based detection. The combined cytokine response is calculated as the averaged response for the 4 cytokines measured relative to the response observed in the vehicle-treated mice, and are depicted as the mean±standard error of the mean (n=8 rats/group). |
References: [1]. Linda N. Casillas, et al. Prodrugs of amino quinazoline kinase inhibitor. PCT Int. Appl. (2014), WO 2014043446 A1 20140320. |